design
synthesi
biolog
evalu
seri
esterderiv
sever
acut
respiratori
syndromecoronaviru
chymotrypsinlik
proteas
inhibitor
describ
posit
carboxyl
function
critic
potenc
inhibitor
ester
posit
indol
ring
potent
inhibitor
sarscov
ic
valu
nm
antivir
ec
valu
lm
molecular
dock
studi
provid
possibl
bind
mode
inhibitor
sinc
first
appear
southern
china
late
sever
acut
respiratori
syndrom
sar
recogn
global
threat
affect
individu
countri
caus
nearli
fatal
worldwid
within
month
caus
pathogen
novel
coronaviru
term
sarscov
sar
contain
world
case
report
sinc
april
expect
epidem
strike
even
sever
form
furthermor
natur
unpredict
outbreak
potenti
threat
global
economi
public
health
date
effect
therapi
exist
viral
ill
sar
coronaviru
positivestrand
rna
viru
twothird
genom
encod
two
overlap
polyprotein
process
gener
viral
replic
complex
viral
replic
replicas
polyprotein
undergo
extens
process
two
viral
proteas
name
chymotrypsinlik
proteas
papainlik
proteas
plpro
essenti
role
viral
replic
proteas
recogn
attract
target
develop
antisar
therapeut
structur
activ
activ
site
sarscov
sarscov
plpro
elucid
thu
far
inhibitor
design
effort
mostli
limit
sarscov
numer
coval
noncoval
inhibitor
report
continu
interest
design
develop
sarscov
inhibitor
recent
report
structurebas
design
number
potent
peptidomimet
sarscov
inhibitor
sarscov
activ
site
contain
catalyt
dyad
cystein
residu
act
nucleophil
histidin
residu
act
gener
acid
base
inhibitor
bind
sarscov
coval
bond
activ
site
residu
inhibitor
contain
peptidomimet
scaffold
lack
adequ
potenc
particularli
antivir
activ
suitabl
drugdevelop
recent
wong
cowork
report
new
class
potent
small
molecul
benzotriazol
esterbas
inhibitor
compound
potent
inhibitor
among
benzotriazol
ester
mode
action
involv
acyl
activ
site
assist
catalyt
dyad
irrevers
enzym
acyl
verifi
electrospray
ioniz
mass
spectrometri
inhibit
enzym
inhibitor
shown
impress
sarscov
enzym
inhibitori
activ
antivir
activ
requir
improv
seem
moieti
play
import
role
bind
enzym
activ
site
anoth
class
hetereoaromat
ester
inhibitor
also
identifi
studi
moieti
prove
key
unit
activ
report
howev
lack
antivir
data
report
herein
develop
esterbas
sarscov
inhibitor
exhibit
potent
enzym
inhibitori
activ
well
good
see
front
matter
elsevi
ltd
right
reserv
sarscov
antivir
activ
cell
cultur
assay
also
carri
molecular
dock
studi
obtain
potenti
bind
mode
inhibitor
gener
synthet
method
ester
inhibitor
outlin
scheme
variou
ester
tabl
synthes
esterif
correspond
carboxyl
acid
mediat
dcc
dmap
ch
cl
synthesi
inhibitor
carri
acetyl
indol
acet
anhydrid
pyridin
reflux
provid
amid
respect
excel
yield
synthesi
inhibitor
outlin
scheme
direct
sulfonamid
indol
regular
tscldmap
condit
higher
temperatur
could
provid
desir
product
increas
reactiv
indol
reduc
indolin
sodium
cyanoborohydrid
excel
yield
result
indolin
readili
react
tosyl
chlorid
chlorid
give
sulfonamid
good
yield
oxid
indolin
correspond
indol
respect
achiev
use
manganes
dioxid
high
temperatur
hydrolysi
methyl
ester
correspond
acid
use
sodium
hydroxid
follow
gener
esterif
method
describ
scheme
afford
target
compound
structur
activ
inhibitor
shown
tabl
enzym
inhibitori
activ
activ
ester
determin
use
fulllength
authent
version
enzym
fretbas
micropl
assay
describ
grumtokar
cowork
assay
perform
micropl
use
reaction
volum
contain
mm
hepe
ph
nm
authent
enzym
mm
dtt
mgml
bsa
vari
concentr
inhibitor
reaction
compon
except
substrat
incub
min
reaction
initi
addit
fretsubstr
hilyt
fluor
tm
tm
nh
give
final
substrat
concentr
lm
describ
ic
valu
inhibitor
determin
measur
rate
reaction
increas
inhibitor
concentr
shown
tabl
known
benzotriazol
ester
inhibitor
evalu
assay
control
inhibitor
benzotriazol
unit
replac
unit
inhibitor
shown
compar
enzymat
inhibitori
potenc
ic
lm
howev
inhibitor
exhibit
antivir
activ
ester
exhibit
antivir
activ
ec
valu
lm
indol
nitrogen
acetyl
result
compound
remain
quit
potent
ic
lm
tosyl
indol
ic
lm
interestingli
nitrobenzenesulfonamid
analog
show
improv
ic
valu
nm
investig
import
howev
exhibit
enzym
ic
valu
lm
gener
indol
free
nitrogen
potent
correspond
protect
analogu
confirm
coval
modifi
determin
enzym
modif
use
malditof
authent
sarscov
incub
compound
min
analyz
comparison
untreat
enzym
shift
approxim
da
observ
treatment
sarscov
inhibitor
confirm
coval
modif
coval
modif
similar
reactiv
ester
also
report
obtain
molecular
insight
bind
properti
activ
esterbas
inhibitor
conduct
dock
studi
activ
site
use
dock
activ
compound
activ
site
authent
sarscov
structur
pdbid
search
obtain
model
associ
complex
unreact
ester
protein
ie
prior
nucleophil
attack
distanc
carbonyl
carbon
atom
sulfur
atom
constrain
rang
prereact
collis
complex
shown
figur
result
distanc
carbonyl
carbon
sulfur
orient
ligand
chloropyridyl
group
situat
pocket
chloro
group
point
toward
surfac
protein
nitrogen
chloropyridinyl
leav
group
close
proxim
imidazol
nitrogen
carbonyl
oxygen
situat
three
backbon
nitrogen
form
three
hydrogen
bond
shown
figur
first
hydrogen
bond
nh
second
nh
third
nh
suggest
fairli
strong
hydrogen
bond
network
present
within
activ
site
like
aid
posit
stabil
carbonyl
group
ester
nucleophil
attack
indol
group
posit
near
hydrophob
pocket
indol
nitrogen
like
interact
imidazol
group
see
figur
next
analyz
interact
postreact
coval
modifi
state
product
reaction
dock
use
recent
releas
crystal
structur
pdbid
crystal
structur
contain
benzotriazol
ester
molecul
react
thiol
form
coval
bound
ligand
similar
compound
present
paper
use
crystal
structur
postreact
complex
due
notabl
movement
flip
abl
p
stack
aromat
moieti
smaller
coval
bound
ligand
model
capabl
dock
coval
bound
ligand
figur
dock
model
coval
attach
sulfur
atom
model
suggest
indol
group
shift
posit
leav
group
complex
toward
pocket
posit
inhibitor
complex
surpris
similar
orient
propos
jame
group
similar
ester
importantli
though
obviou
pp
stack
indolyl
imidazol
ring
also
seen
benzotriazol
group
referenc
crystal
structur
approxim
aromat
ring
indolyl
imidazol
interact
clearli
determin
posit
indolyl
group
compound
residu
shown
figur
away
indolyl
might
come
play
larger
substitu
compound
result
dock
studi
present
suggest
indol
group
potenti
occupi
two
differ
bind
pocket
cours
reaction
dynam
enzymat
rearrang
vicin
recent
suggest
xray
structur
sarscov
react
benzotriazol
suggest
coval
link
indolyl
shift
toward
pocket
stack
shift
imidazol
ring
lock
orient
implic
substitut
indolyl
ring
would
benefici
model
avail
structur
modif
indol
group
tailor
enhanc
interact
pocket
complex
format
readili
occur
time
consid
ligand
must
mobil
enough
occupi
pocket
postreact
conclus
design
strategi
combin
key
part
two
mechanismbas
inhibitor
led
seri
indolecarboxyl
inhibitor
enzymat
potenc
submicromolar
level
posit
carboxyl
acid
ester
critic
potenc
indolecarboxyl
carboxyl
function
potent
inhibitor
enzym
inhibitori
activ
sarscov
ic
nm
antivir
potenc
ec
valu
lm
design
synthesi
effect
inhibitor
progress
laboratori
